Special considerations in diagnosing and treating attention-deficit/ hyperactivity disorder

Primary Psychiatry

Volumn 14, Issue 6, 2007, Pages

  Wigal, Sharon B ^a   Wigal, Timothy L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CATECHOL METHYLTRANSFERASE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOPAMINE 4 RECEPTOR; METHYLPHENIDATE; PLACEBO; PSYCHOSTIMULANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CHILD BEHAVIOR; CHRONIC DISEASE; CLINICAL PRACTICE; COGNITIVE THERAPY; COMORBIDITY; COMPULSION; CONDUCT DISORDER; CONTINUING EDUCATION; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; EMOTIONAL DISORDER; ERECTILE DYSFUNCTION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; LEARNING DISORDER; LONG TERM CARE; MENTAL DISEASE; NAUSEA; NERVOUSNESS; ONSET AGE; OPTIMAL DRUG DOSE; PATIENT COUNSELING; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCHOOL CHILD; PREVALENCE; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL WITHDRAWAL; RECEPTOR GENE; REVIEW; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; SUBSTANCE ABUSE; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 34250886498     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Lavigne JV, Gibbons RD, Christoffel KK, et al. Prevalence rates and correlates of psychiatric disorders among preschool children. J Am Acad Child Adolesc. 1996;32:204-214.
2. Campbell SB. Parent-referred problem three-year-olds: developmental changes in symptoms. J Child Psychol Psychiatry. 1987;28:835-845.
3. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc. 2001;40:508-515.
4. Lahey BB, Pelham WE, Stein MA, et al. Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. J Am Acad Child Adolesc. 1998;37:695-702.
5. LaHoste GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry. 1996;1:121-124.
6. Lahey BB, Pelham WE, Loney J, et al. Three-year predictive validity of DSM-IV attention deficit hyperactivity disorder in children diagnosed at 4Y6 years of age. Am J Psychiatry. 2004;161:2014-2020.
7. Pierce EW, Ewing LJ, Campbell SB. Diagnostic status and symptomatic behavior of hard-to-manage preschool children in middle childhood and early adolescence. J Clin Child Psychol. 1999;28:44-57.
8. Wilens TE, Biederman J, Brown S, Monuteaux M, Prince J, Spencer TJ. Patterns of psychopathology and dysfunction in clinically referred preschoolers. J Dev Behav Pediatr. 2002;23:S31-S36.
9. Medco Health Solutions. 2004 Drug Trend Report. Available at: www.med-cohealth.com. Accessed May 17, 2004.
10. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025-1030.
11. Kollins S, Greenhill L, Swanson J, et al. Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry. 2006;45(11):1275-1283.
12. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
13. Manidiaki K, Sonuga-Barke E, Kakouros E, Karaba R. Parental beliefs about the nature of ADHD behaviours and their relationship to referral intentions in preschool children. Child Health Care Dev. 2007;33:188.
14. NIMH ADHD site. Available at: www.nimh.nih.gov/publicat/adhd.cfm#diag. Accessed May 13, 2007.
15. Consensus Development Panel. Defined Diets and Childhood Hyperactivity. National Institutes of Health Consensus Development Conference Summary. 1982; Vol 4, No 3.
16. Biederman J, Faraone SV, Keenan K, Knee D, Tsuang MF Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1990;29:526-533.
17. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry. 1998;44:951-958.
18. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1313-1323.
19. Kennedy JL. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry. 2004;1:121-124.
20. Lowe N, Kirley A, Hawi Z, et al. Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity attention-deficit/ hyperactivity disorder confined to the predominantly inattentive and combined subtypes. Am J Hum Genet. 2004;74:348-356.
21. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry. 2005;57:1367-1373.
22. El-Faddagh M, Laucht M, Maras A, et al. Association of dopamine D4 receptor (DRD4) gene with attention-deficit/hyperactivity disorder (ADHD) in a high-risk community sample: a longitudinal study from birth to 11 years of age. J Neur Trans. 2004;111:883-889.
23. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc. 2001;40:168-179.
24. Thapar A, Langley K, Fowler T, et al. Catechol o-methyltransferase gene variant and birth weight predict early-onset antisocial behavior in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2005;62:1275-1278.
25. Thapar A, Langley K, O'Donovan M, et al. Refining the attention deficit hyperactivity disorder phenotype for molecular genetic studies. Mol Psychiatry. 2006;11:714-720.
26. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
27. Wender PH. ADHD: Attention-Deficit Hyperactivity Disorder in Children and Adults. Oxford University Press. 2002:9.
28. Geller B, Williams M, Zimerman B, Frazier J, Beringer L, Warner KL. Prepubertal and early adolescent bipolarity differentiate from ADHD by manic symptoms, grandiose delusions, ultra-rapid or ultradian cycling. J Affect Disord. 1998;51:81-91.
29. Barkley RA, The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc. 1998;27:336-341.
30. Cohen NJ. Evaluation of the relative effectiveness of methylphenidate and cognitive behavior modification in the treatment of kindergarten-aged hyperactive children. J Abnormal Child Psychol. 1981;9:43-54.
31. Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc. 1999;38:805-812.
32. Swanson J, Greenhill L, Wigal T, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc. 2006;45:1304-1313.
33. Wigal S, Gupta S, Greenhill L, et al. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. In press.
34. Greenhill L, Kollins S, Abikoff H, et al. Rationale, design, and methods of the preschool ADHD treatment study (PATS). J Am Acad Child Adolesc. 2006;45:11.
35. Sonuga-Barke EJ, Daley D, Thompson M, Laver-Bradbury C, Weeks A. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc. 2001;40:402-408.
36. Olfson M. Diagnosing mental disorders in office-based pediatric practice. J Dev Behav Pediatr. 1992;13:363-365.
37. Frazier T, Youngstrom E, Glutting J, Watkins M. ADHD and achievement: meta-analysis of the child, adolescent, and adult literature and a concomitant study with college students. Journal of Learning Disabilities. 2007;40:49-65.
38. Bagwell C, Molina B, Pelham W, Hoza B. Attention deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40:1285-1292.
39. Pelham W, Foster M, Robb J. The Economic impact of attention-deficit/ hyperactivity disorder in children and adolescents. Ambulatory Pediatrics. 2007;7:121-131.
40. Biederman J, Farone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit/hyperactivity and related disorders. Arch Gen Psychiatry. 1996;53:437-446.
41. Ingram S, Hechtman L, Morgenstern G. Outcome issues in ADHD: adolescent and adult long-term outcome. Ment Retard Dev Disabil Res Rev. 1999;5:243-250.
42. Biederman J, Newcorn JH, Sprich S. Comorbidity of attention-deficit hyperactivity disorder with conduct, depressive, anxiety and other disorders. Am J Psychiatry. 1991;148:251-256.
43. Abikoff H, Courtney M, Pelham WE, Koplewicz HS. Teachers' ratings of disruptive behaviors: the influence of halo effects. J Abnorm Child Psychol. 1993;21:519-533.
44. Schachar R, Sandber S, Rutter M. Agreement between teachers' ratings and observations of hyperactivity, inattentiveness and defiance. J Abnorm Child Psychol. 1986;14:331-345.
45. Pliszka SR. Effect of anxiety on cognition, behavior and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry. 1989;28:882-887.
46. Rappley MD, Gardiner JC, Jetton JR, Houang RT. The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med. 1995;149:675-679.
47. Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Ret Dev Dis Res Rev. 2002;8:162-170.
48. NIMH. Attention Deficit Hyperactivity Disorder. 2DD6. Available at: http://www.nimh.nih.gov/publicat/adhd.cfm#intro. Accessed April 19, 2007.
49. Mental health in the United States: prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(34);842-847.
50. Wilens T. Alcohol and other drug use and attention deficit hyperactivity disorder. Alcohol Health Res World. 1998;22:127-130.
51. Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost group up: I. Psychiatric status. Arch Gen Psychiatry. 1985;42:937-947.
52. Hechtman L, Weiss G. Controlled prospective fifteen year follow-up of hyperactives as adults: non-medical drug and alcohol use and anti-social behaviour. Can J Psychiatry. 1986;31:557-567.
53. Barkley R. Driving Impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:233-260.
54. Johnston C, Mash E. Families of children with attention deficit hyperactivity disorder: review and recommendations for future research. Clin Child Family Psychol. 2001;4:183-207.
55. Biederman J, Wilens T, Mick E, et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry. 1998;36:37-43.
56. Silver LB. The relationship between learning disabilities, hperactivty, distractibility, and behavioral problems. J Am Acad Child Psychiatry. 1981;20:385-397.
57. Biederman J, Faraone SV, Mick E, et al. Attention deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry. 1996;35:997-1008.
58. Spencer J, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology Ambulatory Pediatrics. 2007;7:73-81.
59. Goldman S, Genel M, Bezman R, Slanetz P. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998;279:1100-1107.
60. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 1991;148:564-577.
61. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a 4-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry. 1996;35:1193-1204.
62. Klorman R, Brumaghim JT, Salzman LF et al. Effects of methylphenidate on attention-deficit hyperactivity disorder with and without aggressive/ noncompliant features. J Abnorm Psychol. 1988;97:413-422.
63. Biederman J, Faraone SV, Keenan K, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry. 1992;49:728-738.
64. Brent DA, Perper JA, Goldstein CE, et al. Risk factors for adolescent suicide: a comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry. 1988;45:581-588.
65. Biederman J, Faraone S, Keenan K, et al. Family genetic and psychosocial risk factors in attention deficit disorder. Biol Psychiatry. 1989;25:145A.
66. Morgan A, Hynd G, Riccio C, Hall J. Validity of DSM-IV ADHD predominately inattentive and combined types: relationship to previous DSM diagnoses/subtype differences. J Am Acad Child Adolsec Psychiatry. 1996;35:325-333.
67. Paternite C, Loney J, Roberts M. External validation of oppositional disorder and attention deficit disorder with hyperactivity. J Abnorm Child Psychol. 1995;23:453-471.
68. Wolraich M, Hannah J, Pinnock T, et al. Comparison of diagnostic criteria for attention-deficit hyperacitivty disorder in a country-wide sample. J Am Acad Child Adolesc Psychiatry. 1996;35:319-324.
69. Sleator E, Ullman R. Can the physician diagnose hyperactivity in the office? Pediatrics. 1981;67:13-17.
70. Mitsis E, McKay K, Schulz K, et al. Parent-teacher concordance for DSM-IV attention-deficit/hyperactivity disorder in a clinic-referred sample. Child Adolesc Psychiatry. 2000;39:308-313.
71. Molina B, Pelham W, Blumenthal J, Galiszewski E. Agreement among teachers' behavior ratings of adolescents with a childhood history of attention-deficit/hyperactivity disorder. J Clin Child Psychol. 1998;27:330-339.
72. Kramer T, Phillips S, hargis M, et al. Disagreement between parent and adolescent reports of functional impairment. J Child Psychol Psychiatry. 2004;45:248-259.
73. Kiddie-Sads-Present and Lifetime Version (K-SADS-PL). Available at: http://www.wpic.pitt.edu/ksads/default.htm. Accessed April 19, 2007.
74. Achenbach T, Edelbrock L. Manual for the Child Behavior Checklist 4-18 and 1991 Profile. Burlington, VT: University of Vermont; 1991.
75. Reynolds C, Kamphouse R. BASC: Behavior Assessment System for Children Manual. Circle Pines, MN: American guidance Service; 1992.
76. Brown TE. Brown ADD Scales for Children and Adolescents. San Antonio, TX: Psychological Corp; 2001.
77. Swanson J, Nolan R, Pelham W. Swanson, Nolan and Pelham Rating Scale (SNAP). Pittsburgh, PA, Department of Psychiatry, Western Psychiatric Institute and Clinic; 1998.
78. Shaffer D, Fisher P, Dulcan M, et al. The second version of the NIMH Diagnostic Interview Schedule for Children (DISC-2). J Am Acad Child Adolesc Psychiatry. 1996;35:865-877.
79. Quinn P, Wigal S. Perceptions of girls and ADHD: results from a national survey. Med Gen Med. 2004;6:2.
80. Sharp WS, Walter J, Marsh W, Ritchie G, Hamburger S, Castellanos F. ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry. 1999;38:40-47.
81. Biederman J, Faraone S, Milberger S, et al. Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources. J Am Acad Child Adolesc Psychiatry. 1999;38:966-975.
82. Carlson C, Tamm L, Gaub M. Gender differences in children with ADHD, ODD and co-occurring ADHD/ODD identified in a school population. J Am Acad Child Adolesc Psychiatry. 1997;36:1706-1714.
83. Gaub M, Carlson C. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry. 1997;36:1036-1045.
84. Wigal S, McGough J, McCracken J, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9:275:289.
85. Arnold L. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). Ann N Y Acad Sci. 2001;931:310-341.
86. Wigal S, Wigal T, Kollins S. Advances in methylphenidate drug delivery systems for ADHD therapy. Advances in ADHD. 2006;1:4-7.
87. Biederman J, Monuteaux M, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10 year follow-up study. Psychol Med. 2006;36:167-179.
88. Kessler RC, Adler L, Barkle R, et al. the prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006,163:716-723.
89. Milstein RB, Wilens TE, Biederman J, et al. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Atten Disord. 1997;2:159-166.
90. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162:1621-1627.
91. Biederman J, Faraone SV, Spencer T, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524-540.
92. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;163:716-723.
93. Borland BL, Heckman HK. Hyperactive boys and their brothers: a 25-year follow-up study. Arch Gen Psychiatry. 1976;33:669-675.
94. Morrison JR. Childhood hyperactivity in an adult psychiatric population: social factors. J Clin Psychiatry. 1980;41:40-43.
95. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict. 1998;7:156-163.
96. Tarter RE. Psychosocial history, minimal brain dysfunction and differential drinking patterns of male alcoholics. J Clin Psychol. 1982;38:867-873.
97. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults comorbidities and adaptive impairments. Compr Psychiatry. 1996;37:393-401.
98. Barkley RA, Fischer M, Fletcher K, et al. Persistence of attention deficit hyperactivity disorder into adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111:279-289.
99. Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ 2003;168:715-722.
100. Barkley RA. Major life activity and health outcomes associated with attention deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(Suppl 12):10-5.
101. Shekin WO, Asarnow RF, Hess E, et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990;31:416-425.
102. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comoribidty, cognition, and psychosocial funcitioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792-1798.
103. Kessler RC, Berglund P, Dernier O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions fDSM-IV disorders in the national Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
104. Wilens TE: Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am. 2004;27:283-301.
105. Rush CR, Higgins ST, Vansickel AR, Stoops WW, Lile JA, Glaser PE. Methylphenidate increases cigarette smoking. Psychopharmacology (Berl). 2005;181:781-789.
106. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;11:179-185.
107. Sobanski E. Pschiatric comorbidity in adults with attention-deficity/ hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2006;256:26-31.
108. Wender PH, Reimherr FW, Wood D, Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry. 1985;142:547-552.
109. Markowitz JS. Drug interactions with stimulant medications. Int Clin Psychopharmacol. 1999;14:1-18.
110. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant mediaction in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S-49S.
111. Nierenberg AA, Mihahara S, Spencer T, et al. Clinical and diagnostic implications of lifetime comorbidity of attention-deficit/hyperactivity disorder in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry. 2005:57;1467-1473.
112. Brown TE, McMullen WJ. Attention deficit disorders and sleep/arousal disturbance. Ann NY Acad Sci. 2001;931:271-286.
113. Kooj JJS, Huub AM, Middelkoop AM, Van Gils K, Buitelaar JK. The effect of stimulants on nocturnal activity and sleep quality in adults with ADHD: an open-label case-control study. J Clin Psychiatry. 2001;62:952-955.
114. Manuzza S, Klein RG, Bessler A, Malloy P, La Padula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50:565-567.
115. Faraone SV, Biederman J, Doyle A, et al. Neuropsychological Studies of Late Onset and Subthreshhold Diagnoses of Adult Attention-Deficit/Hyperactivity Disorder. Biol Psychiatry. 2006;60:1081-1087.
116. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:885-890.
117. Wender PH. Attention-Deficit Hyperactivity Disorder in Adults. New York, NY: Oxford University Press; 1995.
118. Donnelly C, Reimherr F, Young J. Differential diagnosis and treatment of adult ADHD and neighboring disorders. CNS Spectr. 2006;10(Suppl 11):1-16.
119. Wigal T, Wigal B, Steinhoff K, et al. Establishing a clinical diagnosis of ADHD in adults: the QUEST method. Advances in ADHD. 2007. In press.
120. Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005;43(7):831-842..
121. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/ hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005;66:294-299.
122. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled trials. Biol Psychiatry. 2003;53:112-120.
123. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65(Suppl 3);38-45.
124. Allen AJ, Kurian RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65:1941-1949.
125. Nissen SE. ADHD and cardiovascular risk. N Engl J Med. 2006;354:1445-1448.
126. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:456-463.
127. Wender EH. Managing stimulant medication for attention-deficit/ hyperactivity disorder. Pediatr Rev. 2001;22:183-189.
128. Dexmethylphenidate (Focalin) for ADHD. Med Lett. 2002;44:45-46.
129. Graydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents. Adolesc Med. 2002;3:599-624